🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆
Clinical Trials in Denmark / NCT06675903
Recruiting Observational

Continuous Glucose Monitoring (CGM) After Kidney Transplantation

NCT06675903 · tracked via the Priya Life Science Denmark tracker
Sponsor
Bo Feldt-Rasmussen
Phase
Observational
Started
2024-11-12
Last updated
2026-08-18

Condition(s) studied

HyperglycaemiaKidney Transplantation

Study summary

This study examines glucose levels measured by continuous glucose monitoring (CGM) in the immediate period following kidney transplantation among recipients with diabetes, without diabetes, and with pre-diabetes.

The primary objective is to analyse differences in mean sensor glucose between these three groups.

CGMs are applied to participants within 72 hours after kidney transplantation, with a total of 54 participants divided equally across the three groups (18 in each).

Secondary objectives include assessing additional glucose profile indices, adherence to relevant guidelines, changes in HbA1c, the impact of immunosuppression and steroid dosage, and beta cell function.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Written informed consent obtained before CGM application * Male or female; age: ≥18 years * Kidney transplantation Exclusion Criteria: * Unable to cooperate to CGM the first ten days after surgery * Allergic to plasters in CGM units * Combined kidney and liver or pancreatic transplantation * Graft loss/rejection within first 48 hours after transplantation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rigshospitalet Copenhagen DK Recruiting

More Bo Feldt-Rasmussen trials in Denmark

Continuous Glucose Monitoring in Dialysis Patients With Diabetes Active, not recruiting

Other trials for the same condition

Multiparametric MRI in a Prospective Cohort of Living Kidney Donors, Recipients, and Healthy Controls: Correlations With Markers of Renal Function, Fibrosis and Ageing Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06675903 on ClinicalTrials.gov ↗ ← All trials in Denmark